Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 5/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6580562 | 0.88 | PTGS1 (0.39) | PDE7AKMT2ABACE1PTGS1PTGS2 | |
| SCHEMBL6582062 | 0.75 | AKR1B1 (0.41) | BACE1PTGS1PTGS2NPC1MAP3K14 | |
| SCHEMBL6605186 | 0.70 | AKR1B1 (0.42) | PDE7APTGS1PTGS2MAP3K14 | |
| SCHEMBL6605188 | 0.70 | AKR1B1 (0.42) | PDE7APTGS1PTGS2MAP3K14 | |
| SCHEMBL6580397 | 0.70 | AKR1B1 (0.42) | PDE7APTGS1PTGS2MAP3K14 | |
| SCHEMBL11367364 | 0.66 | MAP3K14 (0.47) | BACE1NPC1RAB9AMAPTMAP3K14 | |
| SCHEMBL6580916 | 0.64 | RAB9A (0.43) | KMT2ABACE1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6578320 | 0.63 | SMN1; SMN2 (0.42) | KMT2ABACE1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6583197 | 0.63 | AKR1B1 (0.45) | BACE1PTGS1PTGS2MAP3K14 | |
| SCHEMBL6603942 | 0.62 | AKR1B1 (0.33) | MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012140-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-6576657-B2 | Nitrogen containing heterocyclic compounds useful as anticoagulants | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-21 | — | — | US | disclosed |
| US-6265397-B1 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-1012140-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998057932-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | PDE7A 1425/4885KMT2A 4730/4885BACE1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.